Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabametkib Phase 1 in Advanced Solid Tumors
NCT04052971Phase 1Completed
- Sponsor
- ABION Inc.
- Start
- Aug 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of vabametkib in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by ABION Inc. Primary endpoints: Safety and Tolerability of ABN401 and Objective Response Rate up to 30 days. Started Aug 2019; status: completed.
02
Drugs
vabametkib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04052971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052971.